In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congress Approves FDA Reform/User Fee Bill In The Nick Of Time

This article was originally published in The Gray Sheet

Executive Summary

Congress gave final approval last week to a massive FDA bill that renews device and drug user fees for five years and strengthens product safety programs

You may also be interested in...



FDA Gives Congress Reprieve On Deadline For Passing User Fee Bill

Commissioner Gottlieb says agency won't issue layoff notices 'unless and until Sept. 30 passes without reauthorization.'

FDA Gives Congress Reprieve On Deadline For Passing User Fee Bill

Commissioner Gottlieb says agency won't issue layoff notices 'unless and until Sept. 30 passes without reauthorization.'

Obamacare Repeal May Be Delaying User-Fee Bills, Rep. DeGette Says

The House Energy and Commerce Committee Democrat says few in-depth member talks about user-fee bills have taken place because of a focus on Affordable Care Act repeal and replacement.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025278

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel